Home > News > Nanogen Expands Real-Time Portfolio
April 25th, 2006
Nanogen Expands Real-Time Portfolio
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products announced today it has expanded its molecular reagent product portfolio to include real-time probes and primers designed to detect the presence of Epstein-Barr virus (EBV). EBV is the causative agent of infectious mononucleosis and also underlies several other lymphoproliferative disorders such as Burkitt's lymphoma.
Source:
Nanogen
Bookmark:
| Related News Press |
Nanomedicine
Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017
Learning with light: New system allows optical “deep learning”: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017
Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017
Announcements
Rice U. chemists create 3-D printed graphene foam June 22nd, 2017
Tiny bubbles provide tremendous propulsion in new microparticles research-Ben-Gurion U. June 21st, 2017
Enhanced photocatalytic activity by Cu2O nanoparticles integrated H2Ti3O7 nanotubes June 21st, 2017
Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||